Search Within

Mark E Robson

  1. "2024"
Formats
  1. Journal Article (18)
  2. Meeting Abstract (11)
  3. Guidelines (3)
Groups
  1. Breast Medicine Service (32)
  2. Department of Medicine (32)
  3. Population Sciences Research Program (32)
  4. Solid Tumor Oncology Division (32)
  5. Survivorship Research (32)
  6. Epidemiology and Biostatistics (13)

More Groups

People
  1. Anton Safonov (8)
  2. Pedram Razavi (8)
  3. Larry Norton (7)
  4. Yuan Chen (7)
  5. Sarat Chandarlapaty (6)
  6. Shanu Modi (6)

More People

Years
  1. 2024 (32)
Publications
  1. Journal of Clinical Oncology (8)
  2. Annals of Oncology (4)
  3. npj Breast Cancer (4)
  4. JAMA Network Open (2)
  5. Asia-Pacific Journal of Oncology Nursing (1)
  6. Breast Cancer Research and Treatment (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (10)
  2. Nature Publishing Group (6)
  3. Oxford University Press (4)
  4. American Medical Association (2)
  5. Elsevier Science, Inc. (2)
  6. Elsevier Inc. (1)

More Publishers

Results (32)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • HOPE: Harnessing olaparib, palbociclib, and endocrine therapy for BRCA1/2-associated HR+, HER2- metastatic breast cancer
    Meeting Abstract

    Shah, P. D.; Torres, A.; Aaron, M.; Narayan, V.; Knollman, H. M.; Bradbury, A. R.; DeMichele, A.; Robson, M. E.; Tung, N. M.; Domchek, S. M.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2-early breast cancer (EBC) treated with endocrine therapy (ET) in the US
    Meeting Abstract

    Razavi, P.; Ahmed, M.; Roush, A.; Parikh, R.; Hitchens, A.; Shen, S.; Safonov, A.; Jhaveri, K. L.; Robson, M. E.; Peacock, N. W.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Personalized circulating tumor DNA for minimal residual disease and dynamic assessment in patients undergoing neoadjuvant chemotherapy for breast cancer: Preliminary analysis from MSK-LINC
    Meeting Abstract

    Kim, H. K.; An, J. A. R.; Smith, C. G.; Kim, J.; Cabel, L.; Moiso, E.; Ferraro, E.; Safonov, A.; Nelson, K.; Szuhany, K.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Immunotherapy related patient-reported outcomes from five randomized controlled trials in patients with triple negative breast cancer: A systematic review
    Meeting Abstract

    Sha, C.; Liu, M.; Goldberg, J.; Norton, L.; Robson, M. E.; Zhi, I.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Overall survival analysis of first line CDK4/6 inhibitors in a large real-world cohort of patients with hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer
    Meeting Abstract

    Ferraro, E.; Moiso, E.; Safonov, A.; Cabel, L.; Loudon, L.; Dang, C. T.; Shen, S.; Jhaveri, K. L.; Robson, M. E.; Chandarlapaty, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Predicting CDK4/6 inhibitors outcomes in pts with HR+/HER2-metastatic breast cancer: A machine learning approach
    Meeting Abstract

    Moiso, E.; Ferraro, E.; Cabel, L.; Safonov, A.; Ahmed, M.; An, J. A. R.; Jhaveri, K. L.; Norton, L.; Robson, M. E.; Modi, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer
    Journal Article

    Tai, Y.; Chow, A.; Han, S.; Coker, C.; Ma, W.; Gu, Y.; Estrada Navarro, V.; Kandpal, M.; Hibshoosh, H.; Kalinsky, K.; more...
    EMBO Molecular Medicine (2024)

    Fulltext@MSK | Save
  • Pathologic complete response to KEYNOTE522 and HER2-directed therapy for synchronous TNBC and HER2+ breast cancer
    Journal Article

    Mai, N.; Chen, J. F.; Rana, S.; Robson, M.; Chandarlapaty, S.; Rosen, E. Y.
    npj Precision Oncology (2024)

    Fulltext@MSK | Save
  • Pathologic complete response after neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers
    Journal Article

    Myers, S. P.; Sevilimedu, V.; Barrio, A. V.; Tadros, A. B.; Mamtani, A.; Robson, M. E.; Morrow, M.; Lee, M. K.
    npj Breast Cancer (2024)

    Fulltext@MSK | Save
  • The impact of previous therapy on overall-survival in registration clinical trials for 1st line metastatic breast cancer a systemic review
    Journal Article

    Remilah, A. A.; Krayim, B.; Amir, E.; Tibau, A.; Robson, M. E.; Abuhadra, N.; Chen, Y.; Shepshelovich, D.; Goldvaser, H.
    Critical Reviews in Oncology/Hematology (2024)

    Fulltext@MSK | Save